11. (1) Every nuclear energy worker who becomes aware that she is pregnant shall immediately inform the licensee in writing.

(2) On being informed by a nuclear energy worker that she is pregnant, the licensee shall, in order to comply with section 13, make any accommodation that will not occasion costs or business inconvenience constituting undue hardship to the licensee.

12. (1) The definitions in this subsection apply in section 13.

“ALI”

“ALI” or “annual limit on intake” means the activity, in becquerel, of a radionuclide that will deliver an effective dose of 20 mSv during the 50-year period after the radionuclide is taken into the body of a person 18 years old or older or during the period beginning at intake and ending at age 70 after it is taken into the body of a person less than 18 years old. (LAI ou limite annuelle d’incorporation)

“E”

“E” means the portion of the effective dose, in millisievert

• (a) received by a person from sources outside the body; and

• (b) received by and committed to the person from sources inside the body, measured directly or from excreta. (E)

“I”

“I” means the activity, in becquerel, of any radionuclide that is taken into the body, excluding the radon progeny and the activity of other radionuclides accounted for in the determination of E. (I)

“Rn”

“Rn” means the average annual concentration in the air, in Bq per m³, of radon 222 that is attributable to a licensed activity. (Rn)

“RnP”

“RnP” means the exposure to radon progeny in working level months. (RnP)

“Σ I/ALI”

“Σ I/ALI” means the sum of the ratios of I to the corresponding ALI. (Σ I/LAI)

(2) For the purposes of sections 13 and 14, doses of radiation include those received from X-rays or other man-made sources of radiation.

13. (1) Every licensee shall ensure that the effective dose received by and committed to a person described in column 1 of an item of the table to this subsection, during the period set out in column 2 of that item, does not exceed the effective dose set out in column 3 of that item.

(2) For the purpose of item 1 of the table to subsection (1), the effective dose shall be calculated using the following formula and expressed in millisievert:

(3) For the purpose of item 2 of the table to subsection (1), the effective dose shall be calculated using the following formula and expressed in millisievert:

(4) For the purpose of item 3 of the table to subsection (1), the effective dose shall be calculated using either of the following formulas and expressed in millisievert:

(5) For the purpose of subsection (1), where the end of a dosimeter-wearing period or a bioassay-sampling period does not coincide with the end of a dosimetry period set out in column 2 of the table to that subsection, the licensee may extend or reduce the dosimetry period to a maximum of two weeks so that the end of the dosimetry period coincides with the end of the dosimeter-wearing period or biossay-sampling period, as the case may be.